As canagliflozin is metabolized and excreted by UGT1A9 and UDP glucuronosyltransferase family 2 member B4 (UGT2B4), we speculate that cancer cells expressing SGLT2 combined with low levels of UGT1A9 and UGT2B4, will make these tumor cells sensitive to canagliflozin. Here, UGT1A9 is linked to neoplasm.